Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Acquired by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC lifted its holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK) by 1.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 108,799 shares of the biotechnology company’s stock after acquiring an additional 1,794 shares during the quarter. Segall Bryant & Hamill LLC owned 0.74% of Anika Therapeutics worth $2,687,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Stonepine Capital Management LLC grew its position in Anika Therapeutics by 171.4% during the 2nd quarter. Stonepine Capital Management LLC now owns 165,397 shares of the biotechnology company’s stock worth $4,190,000 after purchasing an additional 104,448 shares during the period. Riverwater Partners LLC grew its holdings in Anika Therapeutics by 539.1% during the third quarter. Riverwater Partners LLC now owns 101,996 shares of the biotechnology company’s stock worth $2,552,000 after acquiring an additional 86,037 shares during the period. Meros Investment Management LP raised its position in Anika Therapeutics by 25.0% during the second quarter. Meros Investment Management LP now owns 212,714 shares of the biotechnology company’s stock valued at $5,388,000 after acquiring an additional 42,587 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Anika Therapeutics by 6.9% in the second quarter. Renaissance Technologies LLC now owns 598,229 shares of the biotechnology company’s stock valued at $15,153,000 after acquiring an additional 38,412 shares during the period. Finally, Boston Partners purchased a new stake in Anika Therapeutics in the 1st quarter worth approximately $733,000. Hedge funds and other institutional investors own 91.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on ANIK shares. StockNews.com cut shares of Anika Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, November 4th. Barrington Research dropped their target price on Anika Therapeutics from $37.00 to $25.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st.

Anika Therapeutics Price Performance

Shares of NASDAQ:ANIK opened at $16.97 on Friday. The firm has a market capitalization of $248.61 million, a price-to-earnings ratio of -2.62 and a beta of 0.86. The business’s 50 day moving average price is $22.38 and its 200-day moving average price is $24.76. Anika Therapeutics, Inc. has a 1 year low of $16.00 and a 1 year high of $29.11.

Anika Therapeutics Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.